Brose MS et al. Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Results from the phase 3 COSMIC-311 trial. ASCO 2021;Abstract 6001.

Doebele RC et al. An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101. Cancer Discov 2015;5(10):1049-57. Abstract

Hong DS et al. Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer. ASCO 2021;Abstract 3108.

Hu M et al. Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC). ESMO 2020;Abstract 1913O.

Stransky N et al. The landscape of kinase fusions in cancer. Nat Commun 2014;5:4846. Abstract

Subbiah V et al. Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. ASCO 2020;Abstract 109.

Vaishnavi A et al. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov 2015;5(1):25-34. Abstract

Wirth LJ et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med 2020;383(9):825-35. Abstract